These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
342 related articles for article (PubMed ID: 32226541)
1. IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer. Zhao T; Jin F; Xiao D; Wang H; Huang C; Wang X; Gao S; Liu J; Yang S; Hao J Theranostics; 2020; 10(9):4088-4100. PubMed ID: 32226541 [TBL] [Abstract][Full Text] [Related]
2. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer. Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599 [TBL] [Abstract][Full Text] [Related]
3. SCF, regulated by HIF-1α, promotes pancreatic ductal adenocarcinoma cell progression. Gao C; Li S; Zhao T; Chen J; Ren H; Zhang H; Wang X; Lang M; Liu J; Gao S; Zhao X; Sheng J; Yuan Z; Hao J PLoS One; 2015; 10(3):e0121338. PubMed ID: 25799412 [TBL] [Abstract][Full Text] [Related]
4. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer. Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152 [TBL] [Abstract][Full Text] [Related]
5. TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma. Shang M; Weng L; Xu G; Wu S; Liu B; Yin X; Mao A; Zou X; Wang Z J Cell Physiol; 2021 Oct; 236(10):6868-6883. PubMed ID: 33629745 [TBL] [Abstract][Full Text] [Related]
6. HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signaling pathway. Zhao F; Yang G; Qiu J; Liu Y; Tao J; Chen G; Su D; You L; Zheng L; Zhang T; Zhao Y Mol Carcinog; 2022 Sep; 61(9):839-850. PubMed ID: 35785493 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Zhao T; Ren H; Jia L; Chen J; Xin W; Yan F; Li J; Wang X; Gao S; Qian D; Huang C; Hao J Oncotarget; 2015 Feb; 6(4):2250-62. PubMed ID: 25544770 [TBL] [Abstract][Full Text] [Related]
9. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia. McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621 [TBL] [Abstract][Full Text] [Related]
10. Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin. Zhao X; Gao S; Ren H; Sun W; Zhang H; Sun J; Yang S; Hao J Cancer Res; 2014 May; 74(9):2455-64. PubMed ID: 24599125 [TBL] [Abstract][Full Text] [Related]
11. CypA, a gene downstream of HIF-1α, promotes the development of PDAC. Zhang H; Chen J; Liu F; Gao C; Wang X; Zhao T; Liu J; Gao S; Zhao X; Ren H; Hao J PLoS One; 2014; 9(3):e92824. PubMed ID: 24662981 [TBL] [Abstract][Full Text] [Related]
12. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism. Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382 [TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible factor-1α expression and gemcitabine chemotherapy for pancreatic cancer. Kasuya K; Tsuchida A; Nagakawa Y; Suzuki M; Abe Y; Itoi T; Serizawa H; Nagao T; Shimazu M; Aoki T Oncol Rep; 2011 Dec; 26(6):1399-406. PubMed ID: 21922147 [TBL] [Abstract][Full Text] [Related]
14. RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma. Tu Q; Liu X; Yao X; Li R; Liu G; Jiang H; Li K; Chen Q; Huang X; Chang Q; Xu G; Zhu H; Shi P; Zhao B J Exp Clin Cancer Res; 2022 Sep; 41(1):274. PubMed ID: 36109793 [TBL] [Abstract][Full Text] [Related]
15. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562 [TBL] [Abstract][Full Text] [Related]
16. Glycolysis and tumor progression promoted by the m Yang K; Zhong Z; Zou J; Liao JY; Chen S; Zhou S; Zhao Y; Li J; Yin D; Huang K; Li Y Cancer Lett; 2024 May; 590():216840. PubMed ID: 38604311 [TBL] [Abstract][Full Text] [Related]
17. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis. Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243 [TBL] [Abstract][Full Text] [Related]
18. A nicotine-induced positive feedback loop between HIF1A and YAP1 contributes to epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma. Ben Q; An W; Sun Y; Qian A; Liu J; Zou D; Yuan Y J Exp Clin Cancer Res; 2020 Sep; 39(1):181. PubMed ID: 32894161 [TBL] [Abstract][Full Text] [Related]
19. Vav1-dependent Rac1 activation mediates hypoxia-induced gemcitabine resistance in pancreatic ductal adenocarcinoma cells through upregulation of HIF-1α expression. Zhu C; Hu H; Ma Y; Xiong S; Zhu D Cell Biol Int; 2023 Nov; 47(11):1835-1842. PubMed ID: 37545183 [TBL] [Abstract][Full Text] [Related]
20. Hypoxia-inducible factor-1α regulates chemotactic migration of pancreatic ductal adenocarcinoma cells through directly transactivating the CX3CR1 gene. Zhao T; Gao S; Wang X; Liu J; Duan Y; Yuan Z; Sheng J; Li S; Wang F; Yu M; Ren H; Hao J PLoS One; 2012; 7(8):e43399. PubMed ID: 22952674 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]